Hepatitis B and Delta Virus Infections: Mechanistic Insights and Clinical Drug Therapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 May 2026 | Viewed by 110
Special Issue Editor
Interests: chronic hepatitis B; hepatitis delta virus coinfection; hepatocellular carcinoma risk; molecular virology of HBV/HDV; host-virus molecular interactions; antiviral drug development; HBV functional cure strategies; immune modulation in hepatitis; clinical management of HBV/HDV; pharmacological therapies for viral hepatitis
Special Issue Information
Dear Colleagues,
Despite the availability of an effective prophylactic vaccine, Hepatitis B Virus (HBV) infection remains a considerable global health issue. As reported by the World Health Organization (WHO), approximately 300 million individuals are chronically infected with the HBV virus. Among them, an estimated 5% are coinfected with Hepatitis Delta Virus (HDV), although this figure is likely underestimated owing to limited routine screening and diagnostic challenges. HDV coinfection is associated with a more severe clinical course, resulting in a more rapid progression to cirrhosis, liver failure, and a markedly increased risk of hepatocellular carcinoma (HCC) compared to HBV monoinfection.
A comprehensive understanding of the molecular mechanisms underlying HBV and HDV replication is essential for identifying novel therapeutic targets. Recent years have seen considerable progress in the development of antiviral agents, including entry inhibitors for HDV and immunomodulatory strategies. Nonetheless, attaining a functional or sterilizing cure for chronic HBV infection remains a significant unmet challenge.
This Special Issue aims to compile high-quality original research articles and authoritative reviews focusing on the mechanistic insights and clinical drug therapy of HBV and HDV infections. Relevant topics include, but are not limited to, immune responses, innovative treatment strategies, and precision medicine approaches.
Through the integration of fundamental, translational, and clinical research, this Special Issue aims to provide a comprehensive and current perspective on the current landscape and future trajectories in the management of HBV and HDV infections.
Dr. Daniele Lombardo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic hepatitis B
- hepatitis delta virus coinfection
- hepatocellular carcinoma risk
- antiviral drug development
- HBV functional cure strategies
- immune modulation in hepatitis
- pharmacological therapies for viral hepatitis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
